We are monitoring the impact of COVID-19 on North America Uterine Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

North America Uterine Cancer Therapeutics Market Research Report – Segmented By Type, Therapy, Country (US, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1411
Pages: 134

North America Uterine Cancer Therapeutics Market Size (2022 to 2027)

The size of the Uterine Cancer Therapeutics Market in North America is expected to reach USD 10.88 Billion by 2027 from USD 8.53 Billion in 2022, growing at a CAGR of 4.98% during the forecast period 2022 to 2027.

Uterine cancer is one of the most commonly prevailing malignant tumors that start in the uterus cells and spread to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. As a result, more therapies have evolved to manage uterine cancer types, including surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.

Rising incidence of endometrial cancer in certain states of United States (Caucasians, Hawaiians, Japanese), increasing research to identify new therapeutic approaches, growing advancements in molecular diagnostics industry to support target specific therapies, and rising demand for effective & better therapy solutions are driving the growth of Uterine Cancer Therapeutics Market in North America. In addition, growing awareness among patients and the presence of highly developed healthcare infrastructure are further fuelling the development of the Uterine Cancer Therapeutics Market in North America.

However, stringent regulatory frameworks and unclear reimbursement policies are expected to limit the growth of the Uterine Cancer Therapeutics market in North America.

This research report on the North American Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:

By Type:

  • Uterine Sarcoma
  • Endometrial Carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Others

By Therapy:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy

By Country:

  • United States
  • Canada
  • Rest of North America

The North American market is estimated to hold the largest share in the global uterine cancer therapeutics market during the forecast period due to the rising prevalence of chronic diseases such as cancer and uterine cancer across the region, uterine cancer is a type of endometrial cancer, one of the most common diseases in North America. In addition, availability of advanced infrastructure, increasing healthcare expenditure, and favorable reimbursement policies. The major countries in the region, such as the US and Canada, significantly contribute to North American regional market growth. Both the countries are estimated to have significant growth in the region due to the growing awareness about the importance and benefits of pre-diagnosis of the disease and the treatment available in the market.

The United States market dominated the North American Uterine cancer market in 2020, and it is likely to continue its growth throughout the forecast period. The market growth is attributed to the advancements in healthcare sectors, growing awareness, and increasing investments by the government. However, according to the American cancer society, it is estimated that nearly about 66,570 new cases of uterine cancer arise in 2022.

KEY MARKET PLAYERS:

A few of the promising companies operating in the North American Uterine Cancer Therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.

1.Introduction             

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods      

                1.4 General Study Assumptions                

2. Research Methodology 

                2.1 Introduction         

                2.2 Research Phases 

           2.2.1 Secondary Research            

           2.2.2 Primary Research 

           2.2.3 Econometric Modelling     

           2.2.4 Expert Validation  

                2.3 Analysis Design    

                2.4 Study Timeline     

3. Overview                 

                3.1 Executive Summary                

                3.2 Key Inferences    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                 

                4.1 Market Drivers     

                4.2 Market Restraints                    

                4.3 Key Challenges    

                4.4 Current Opportunities in the Market               

5. Market Segmentation    

                5.1 By Type   

           5.1.1 Endometrial Carcinoma     

      5.1.2.1 Adenocarcinoma

      5.1.2.2 Carcinosarcoma

      5.1.2.3 Squamous cell carcinoma

      5.1.2.4 Others

           5.1.2 Uterine Sarcoma  

                5.2 By Therapy                 

           5.2.1 Surgery    

           5.2.2 Chemotherapy     

           5.2.3 Radiation Therapy

           5.2.4 Immunotherapy   

           5.2.5 Hormone Therapy

6. Geographical Analysis    

                6.1 Introduction         

                6.2 United States       

                6.3 Canada    

7. Pipeline Product Analysis                   

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline

                7.4 Clinical Trials         

           7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

           7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

           7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                   

                8.1 PESTLE analysis    

           8.1.1 Political     

           8.1.2 Economic 

           8.1.3 Social         

           8.1.4 Technological         

           8.1.5 Legal          

           8.1.6 Environmental      

                8.2 Porter’s Five analysis         

           8.2.1 Bargaining Power of Suppliers        

           8.2.2 Bargaining Power of Consumers    

           8.2.3 Threat of New Entrants     

           8.2.4 Threat of Substitute Products and Services

           8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis

                9.1 Abbott Laboratories (U.S.)                   

                                9.1.1 Overview

           9.1.2 Product Analysis   

           9.1.3 Financial analysis  

           9.1.4 Recent Developments       

           9.1.5 SWOT analysis       

           9.1.6 Analyst View          

                9.2 Ariad Pharmaceuticals, Inc. (U.S.)

                9.3 Becton, Dickinson and Company (U.S.)      

                9.4 F. Hoffmann-La Roche AG (Switzerland)   

                9.5 GlaxoSmithKline Plc (U.K.)                   

                9.6 Merck & Co., Inc. (U.S.)    

                9.7 Novartis AG (Switzerland)                    

                9.8 Sanofi (France)    

                9.9 Siemens Healthcare GmbH (Germany)      

                9.10 Takeda Pharmaceutical Company Ltd. (Japan)     

10.Competitive Landscape

                10.1 Market share analysis     

                10.2 Merger and Acquisition Analysis

                10.3 Agreements, collaborations and Joint Ventures  

                10.4 New Product Launches  

11.Market Outlook & Investment Opportunities          

Appendix 

                a) List of Tables                

                b) List of Figures      

  1. North America Uterine Cancer Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. North America Uterine Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  3. North America Endometrial Carcinoma Market By Region, From 2022 - 2027 (USD Billion)
  4. North America Uterine Sarcoma Market By Region, From 2022 - 2027 (USD Billion)
  5. North America Uterine Cancer Therapeutics Market By Therapy, From 2022 - 2027 (USD Billion)
  6. North America Uterine Cancer Surgery Market By Region, From 2022 - 2027 (USD Billion)
  7. North America Uterine Cancer Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  8. North America Uterine Cancer Immunotherapy Market By Region, From 2022 - 2027 (USD Billion)
  9. North America Uterine Cancer Radiation Therapy Market By Region, From 2022 - 2027 (USD Billion)
  10. North America Uterine Cancer Hormone Therapy Market By Region, From 2022 - 2027 (USD Billion)
  11. United States Uterine Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  12. United States Uterine Cancer Therapeutics Market By Therapy, From 2022 - 2027 (USD Billion)
  13. Canada Uterine Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  14. Canada Uterine Cancer Therapeutics Market By Therapy, From 2022 - 2027 (USD Billion)
  15. North America Endometrial Carcinoma Market By Type, From 2022 - 2027 (USD Billion)
  16. North America Adenocarcinoma Market By Region, From 2022 - 2027 (USD Billion)
  17. North America Carcinosarcoma Market By Region, From 2022 - 2027 (USD Billion)
  18. North America Squamous cell carcinoma Market By Region, From 2022 - 2027 (USD Billion)
  19. North America Other Endometrial Carcinoma Market By Region, From 2022 - 2027 (USD Billion)
  20. United States Endometrial Carcinoma Market By Type, From 2022 - 2027 (USD Billion)
  21. Canada Endometrial Carcinoma Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample